NCT03399903 - Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

March 22, 2019

Study Completion Date

March 22, 2019

Conditions

HIV-1-infectionGut Inflammation

Interventions

DRUG

Pentasa vs Align

We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.

Trial Locations (1)

90027

AIDS Healthcare Foundation - Public Health Division, Los Angeles